Profil
Dr. Herwig Gutzeit is Head-Cell Technology & Pharmacology at KINARIS Biomedicals GmbH.
He is on the Board of Directors at Dresden University of Technology.
Dr. Gutzeit was previously employed as a Principal by University of Freiburg.
He received his graduate degree from the University of Oxford and a doctorate degree from the University of Basel.
Aktive Positionen von Herwig Gutzeit
| Unternehmen | Position | Beginn |
|---|---|---|
Dresden University of Technology
Dresden University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Herwig Gutzeit
| Unternehmen | Position | Ende |
|---|---|---|
University of Freiburg
University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
KINARIS Biomedicals GmbH
KINARIS Biomedicals GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures bioactive drugs targeting cellular motor proteins | Gründer | - |
Ausbildung von Herwig Gutzeit
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
University of Freiburg
University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Basel
University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dresden University of Technology
Dresden University of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
KINARIS Biomedicals GmbH
KINARIS Biomedicals GmbH Pharmaceuticals: MajorHealth Technology Develops and manufactures bioactive drugs targeting cellular motor proteins | Health Technology |
















